Brind.
  1. Alector is developing latozinemab in collaboration with GSK, and the FDA granted Breakthrough Therapy designation for the drug, which targets FTD-GRN.

Mizuho upgraded Alector on August 1, 2025, based on the anticipation of positive Phase 3 trial data for latozinemab, Alector's lead asset for FTD, expected in Q4 2025.

1 report, 1 independent Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Mizuho upgraded Alector on August 1, 2025, based on the anticipation of positive Phase 3 trial data for latozinemab, Alector's lead asset for FTD, expected in Q4 2025.

Who's involved

What this event is mainly about
Alector (United States)Mizuho Securities

Keep exploring

Part of

Alector is developing latozinemab in collaboration with GSK, and the FDA granted Breakthrough Therapy designation for the drug, which targets FTD-GRN. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyMizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation Alector Inc. (NASDAQ:ALEC) is one of the stocks under $10 to buy now. On July 28, Mizuho upg